DNA

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to...

Ultima Genomics expands global access to high-quality, low-cost DNA sequencing on the UG 100™ sequencing platform through partnerships with multiple premier genomic services providers

FREMONT, Calif., Feb. 25, 2025 /PRNewswire/ -- Ultima Genomics, Inc., developer of the UG100™ next-generation sequencing (NGS) platform, today announced expanded...

error: Content is protected !!